DrugPatentWatch Database Preview
Litigation Details for ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)
ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)
| Docket | Start Trial | Date Filed | 2006-04-28 |
| Court | District Court, D. New Jersey | Date Terminated | 2009-09-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | None | Referred To | Magistrate Judge Tonianne J. B |
| Parties | GILBERTO FELIX; JONATHAN LEE RICHES; RANBAXY INC.; RANBAXY LABORATORIES LIMITED; ROCHE PALO ALTO LLC | ||
| Patents | 4,355,032; 6,083,953 | ||
| Attorneys | BROOKS R. BRUNEAU; DAVID E. DELORENZI; DIANE C. RAGOSA; ERICA SUSAN HELMS; GILBERTO FELIX; JEFFREY Z.Y. LIAO; JONATHAN LEE RICHES; KAREN A. CONFOY; KRISTINE L. BUTLER; ROBERT G. SHEPHERD; SHEILA F. MCSHANE; THOMAS J. MELORO , JR.; VINNY LEE | ||
| Firms | Gilberto Felix; Parker Ibrahim & Berg LLC; WILLIAMSBURG, FEDERAL CORRECTIONAL INSTITUTION, Inmate Mail/Parcels; Willkie Farr & Gallagher, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED
The small molecule drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2008-03-19 | 135 | United States Patent, No. 6,083,953 (the “953 Patent”). Ranbaxy argues that the ‘953 Patent is invalid … the ‘953 Patent. (Liao Decl. Ex. 9 at R0043851). On October 14, 1999, before the patent issued, Roche…entitled to a patent unless he himself did not invent the subject matter sought to be patented. 35 U.S.C…of an actual inventor from a patent, the court must declare the patent invalid. Id. at 1349. A party…rendered the patent invalid. Section 256 affords the opportunity to correct the patent.”); see also S | External link to document | |
| 2009-02-17 | 277 | infringement of Roche’s U.S. Patent No. 6,083,953 (“the ‘953 patent”). This action was precipitated…evidence” of the patent, viz., the claim language itself, the patent specification and the patent's prosecution… of Roche’s ‘953 patent. B. CMV, Valcyte, And The ’953 Patent 2. Cytomegalovirus…product would not infringe the ’953 patent because the patent requires the claimed valganciclovir hydrochloride…Compounds Of The ‘953 Patent Claims 122. The compounds of the ‘953 patent claims are mono-ester | External link to document | |
| 2009-09-30 | 302 | Roche, as the assignee of U.S. Patent No. 4,355,032 that described and claimed ganciclovir…Roche’s United States Patent No. 6,083,953 (the “‘953 patent”). The ‘953 patent includes claims to the… Beauchamp”) prior patent, United States Patent No. 5,043,339 (the “‘339 patent”), and papers teach… Patent Cooperation Treaty PTO Patent and Trademark Office…collectively, “Ranbaxy”) for patent infringement in violation of the Patent and the Food and Drug Laws | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
